Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.02
Nov 18 • 3:59 PM ET Dollar change+0.14 Percentage change(4.86%)
Aftermarket Close
3.02
Aftermarket • 7:57 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
254.64M
Enterprise Value
214.51M
Income
20.55M
Sales
84.69M
Book/sh
0.98
Cash/sh
0.58
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
226
IPO
Apr 09, 1996
P/E
12.31
Forward P/E
25.17
PEG
-
P/S
3.01
P/B
3.09
P/C
5.17
P/FCF
16.91
EV/EBITDA
8.00
EV/Sales
2.53
Quick Ratio
2.14
Current Ratio
3.27
Debt/Eq
0.11
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
0.25
EPS next Y
0.12
EPS next Q
-0.04
EPS this Y
450.00%
EPS next Y
-57.14%
EPS next 5Y
-
EPS past 3/5Y
35.12% 17.78%
Sales past 3/5Y
3.45% -3.46%
EPS Y/Y TTM
266.67%
Sales Y/Y TTM
36.96%
EPS Q/Q
62.89%
Sales Q/Q
22.82%
Insider Own
9.04%
Insider Trans
0.00%
Inst Own
20.37%
Inst Trans
2.95%
ROA
20.50%
ROE
30.80%
ROIC
23.35%
Gross Margin
71.21%
Oper. Margin
29.76%
Profit Margin
24.27%
SMA20
11.17%
SMA50
11.48%
SMA200
23.06%
Trades
Shs Outstand
82.49M
Shs Float
76.69M
52W High
3.19 -5.33%
52W Low
1.65 83.03%
Volatility
6.17% 5.78%
ATR (14)
0.16
RSI (14)
60.55
Beta
-0.04
Rel Volume
1.12
Avg Volume
859.36K
Volume
962,933
Perf Week
-3.51%
Perf Month
14.39%
Perf Quarter
26.89%
Perf Half Y
50.25%
Perf YTD
67.78%
Perf Year
60.64%
Perf 3Y
115.71%
Perf 5Y
206.19%
Perf 10Y
-38.37%
Prev Close
2.88
Price
3.02
Change %
4.86%
Consensus
Strong Buy
Avg. Price Target
$12.00
Implied Upside
+297.4%
Analysts13incl. previous ratings
Rating Distribution10 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 08, 2020Reiterated
HH.C. Wainwright
Buy$3 → $11+264.2%
Apr 17, 2017Reiterated
RRodman & Renshaw
Buy$4 → $5+65.6%
Apr 04, 2016Initiated
RRodman & Renshaw
Buy$3.50+15.9%
Apr 23, 2015Upgrade
JEF logoJJefferies
Hold → Buy$2 → $2.60-13.9%
Nov 12, 2014Reiterated
RR. F. Lafferty
Buy$8 → $5+65.6%
Jan 24, 2014Initiated
RR. F. Lafferty
Buy$8+164.9%
May 02, 2012Reiterated
OPY logoOOppenheimer
Outperform$9 → $11+264.2%
May 02, 2012Downgrade
CCanaccord Genuity
Buy → Hold$8 → $8+164.9%
Apr 30, 2012Downgrade
AAuriga
Buy → Hold$8 → $8+164.9%
Oct 13, 2011Initiated
MMorgan Joseph
Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bashan DrorPRESIDENT AND CEODec 19 '25Buy1.8156,000101,360188,516Dec 23 07:25 AM
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
PresidentMr. Dror Bashan
Senior VPMr. Gilad Mamlok
MBAMr. Yaron Naos B.Sc.
Vice President of Human ResourcesMs. Yael Fellous